RIGL / Rigel Pharmaceuticals (RIGL) Reports Q4 Loss, Misses Revenue Estimates

SOUTH SAN FRANCISCO, Calif. , Aug. 30, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the compa more_horizontal

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Ray Furey - EVP, General Co more_horizontal

Rigel Pharmaceuticals (RIGL) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares t more_horizontal

Rigel Pharmaceuticals (RIGL) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares t more_horizontal

Rigel Pharmaceuticals Q1 Preview: A 2-Drug Company Pushing For Profitability. more_horizontal

SOUTH SAN FRANCISCO, Calif. , April 25, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first more_horizontal

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Company Participants Ray Furey - EVP, General Cou more_horizontal

Rigel (RIGL) delivered earnings and revenue surprises of 114.29% and 36.56%, respectively, for the quarter ended December 2022. Do the numbers hold cl more_horizontal